730 related articles for article (PubMed ID: 32482597)
1. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.
Campochiaro C; Della-Torre E; Cavalli G; De Luca G; Ripa M; Boffini N; Tomelleri A; Baldissera E; Rovere-Querini P; Ruggeri A; Monti G; De Cobelli F; Zangrillo A; Tresoldi M; Castagna A; Dagna L;
Eur J Intern Med; 2020 Jun; 76():43-49. PubMed ID: 32482597
[TBL] [Abstract][Full Text] [Related]
2. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia.
Capra R; De Rossi N; Mattioli F; Romanelli G; Scarpazza C; Sormani MP; Cossi S
Eur J Intern Med; 2020 Jun; 76():31-35. PubMed ID: 32405160
[TBL] [Abstract][Full Text] [Related]
3. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
Hermine O; Mariette X; Tharaux PL; Resche-Rigon M; Porcher R; Ravaud P;
JAMA Intern Med; 2021 Jan; 181(1):32-40. PubMed ID: 33080017
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review.
Roomi S; Ullah W; Ahmed F; Farooq S; Sadiq U; Chohan A; Jafar M; Saddique M; Khanal S; Watson R; Boigon M
J Med Internet Res; 2020 Sep; 22(9):e21758. PubMed ID: 32784192
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab for severe COVID-19: a systematic review and meta-analysis.
Lan SH; Lai CC; Huang HT; Chang SP; Lu LC; Hsueh PR
Int J Antimicrob Agents; 2020 Sep; 56(3):106103. PubMed ID: 32712333
[TBL] [Abstract][Full Text] [Related]
6. Appropriate use of tocilizumab in COVID-19 infection.
Keske Ş; Tekin S; Sait B; İrkören P; Kapmaz M; Çimen C; Uğur S; Çelebi İ; Bakır VO; Palaoğlu E; Şentürk E; Çağlayan B; Çakar N; Tabak L; Ergönül Ö
Int J Infect Dis; 2020 Oct; 99():338-343. PubMed ID: 32726724
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients.
West TA; Malik S; Nalpantidis A; Tran T; Cannon C; Bhonagiri D; Chan K; Cheong E; Wan Sai Cheong J; Cheung W; Choudhury F; Ernest D; Farah CS; Fernando S; Kanapathipillai R; Kol M; Murfin B; Naqvi H; Shah A; Wagh A; Ojaimi S; Frankum B; Riminton S; Keat K
Int J Rheum Dis; 2020 Aug; 23(8):1030-1039. PubMed ID: 32881350
[TBL] [Abstract][Full Text] [Related]
8. Effective treatment of severe COVID-19 patients with tocilizumab.
Xu X; Han M; Li T; Sun W; Wang D; Fu B; Zhou Y; Zheng X; Yang Y; Li X; Zhang X; Pan A; Wei H
Proc Natl Acad Sci U S A; 2020 May; 117(20):10970-10975. PubMed ID: 32350134
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis.
Mojtabavi H; Saghazadeh A; Rezaei N
Eur Cytokine Netw; 2020 Jun; 31(2):44-49. PubMed ID: 32933891
[TBL] [Abstract][Full Text] [Related]
10. Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019.
Melody M; Nelson J; Hastings J; Propst J; Smerina M; Mendez J; Guru P
Immunotherapy; 2020 Oct; 12(15):1121-1126. PubMed ID: 32546029
[No Abstract] [Full Text] [Related]
11. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study.
Zhang J; Hao Y; Ou W; Ming F; Liang G; Qian Y; Cai Q; Dong S; Hu S; Wang W; Wei S
J Transl Med; 2020 Oct; 18(1):406. PubMed ID: 33121497
[TBL] [Abstract][Full Text] [Related]
12. Preemptive interleukin-6 blockade in patients with COVID-19.
Guillén L; Padilla S; Fernández M; Agulló V; García JA; Telenti G; García-Abellán J; Botella Á; Gutiérrez F; Masiá M
Sci Rep; 2020 Oct; 10(1):16826. PubMed ID: 33033405
[TBL] [Abstract][Full Text] [Related]
13. Clinical risk score to predict in-hospital mortality in COVID-19 patients: a retrospective cohort study.
Fumagalli C; Rozzini R; Vannini M; Coccia F; Cesaroni G; Mazzeo F; Cola M; Bartoloni A; Fontanari P; Lavorini F; Marcucci R; Morettini A; Nozzoli C; Peris A; Pieralli F; Pini R; Poggesi L; Ungar A; Fumagalli S; Marchionni N
BMJ Open; 2020 Sep; 10(9):e040729. PubMed ID: 32978207
[TBL] [Abstract][Full Text] [Related]
14. Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm.
Guo C; Li B; Ma H; Wang X; Cai P; Yu Q; Zhu L; Jin L; Jiang C; Fang J; Liu Q; Zong D; Zhang W; Lu Y; Li K; Gao X; Fu B; Liu L; Ma X; Weng J; Wei H; Jin T; Lin J; Qu K
Nat Commun; 2020 Aug; 11(1):3924. PubMed ID: 32764665
[TBL] [Abstract][Full Text] [Related]
15. TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol.
Piccirillo MC; Ascierto P; Atripaldi L; Cascella M; Costantini M; Dolci G; Facciolongo N; Fraganza F; Marata A; Massari M; Montesarchio V; Mussini C; Negri EA; Parrella R; Popoli P; Botti G; Arenare L; Chiodini P; Gallo C; Salvarani C; Perrone F
Contemp Clin Trials; 2020 Nov; 98():106165. PubMed ID: 33031955
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness.
Rubio-Rivas M; Ronda M; Padulles A; Mitjavila F; Riera-Mestre A; García-Forero C; Iriarte A; Mora JM; Padulles N; Gonzalez M; Solanich X; Gasa M; Suarez-Cuartin G; Sabater J; Perez-Fernandez XL; Santacana E; Leiva E; Ariza-Sole A; Dallaglio PD; Quero M; Soriano A; Pasqualetto A; Koo M; Esteve V; Antoli A; Moreno-Gonzalez R; Yun S; Cerda P; Llaberia M; Formiga F; Fanlo M; Montero A; Chivite D; Capdevila O; Bolao F; Pinto X; Llop J; Sabate A; Guardiola J; Cruzado JM; Comin-Colet J; Santos S; Jodar R; Corbella X
Int J Infect Dis; 2020 Dec; 101():290-297. PubMed ID: 33035673
[TBL] [Abstract][Full Text] [Related]
17. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy.
Montesarchio V; Parrela R; Iommelli C; Bianco A; Manzillo E; Fraganza F; Palumbo C; Rea G; Murino P; De Rosa R; Atripaldi L; D'Abbraccio M; Curvietto M; Mallardo D; Celentano E; Grimaldi AM; Palla M; Trojaniello C; Vitale MG; Million-Weaver SL; Ascierto PA
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32784217
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size.
Zhao H; Zhu Q; Zhang C; Li J; Wei M; Qin Y; Chen G; Wang K; Yu J; Wu Z; Chen X; Wang G
Biomed Pharmacother; 2021 Jan; 133():110825. PubMed ID: 33378989
[TBL] [Abstract][Full Text] [Related]
19. Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain.
Chamorro-de-Vega E; Rodriguez-Gonzalez CG; Manrique-Rodríguez S; Lobato-Matilla E; García-Moreno F; Olmedo M; Correa-Rocha R; Valerio M; Aldámiz-Echevarria T; Machado M; Sancho-Gonzalez M; Lopez-Bernaldo-de-Quirós JC; Ruiz-Briones P; Romero-Jiménez R; Sarobe-González C; Gimenez-Manzorro A; Collado-Borrell R; Fernandez-Llamazares CM; Revuelta-Herrero JL; Somoza-Fernandez B; Garcia-Sanchez S; Taladriz-Sender I; Bouza E; Herranz A; Muñoz P; Sanjurjo M
Expert Rev Clin Pharmacol; 2021 Feb; 14(2):249-260. PubMed ID: 33499687
[No Abstract] [Full Text] [Related]
20. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE).
Colaneri M; Bogliolo L; Valsecchi P; Sacchi P; Zuccaro V; Brandolino F; Montecucco C; Mojoli F; Giusti EM; Bruno R; The Covid Irccs San Matteo Pavia Task Force
Microorganisms; 2020 May; 8(5):. PubMed ID: 32397399
[No Abstract] [Full Text] [Related]
[Next] [New Search]
